List view / Grid view



Night on Highway 128

19 March 2008 | By

Most people in molecular biology today are not old enough to remember pre-PCR. But try to do your job without it and you will see what a difference that simple little technique has made. ‘Polymerase Chain Reaction’ is now a word in Merriam Webster’s Collegiate Dictionary and if you put…

The role of chemokines in type 1 diabetes: as assessed by RT-PCR

19 March 2008 | By

Type 1 diabetes is an autoimmune disease, characterised by immune infiltration into the islets of Langerhans, resulting in the destruction of insulin producing b-cells. Over recent years, evidence has been collected on the important role of chemokines in the recruitment of immune cells leading to the pathology of this disease.…

Antibody-based proteomics to study cellular signalling networks

19 March 2008 | By

The complexity of drug discovery faces many challenges; principally, the failure of drug candidates during the development process as a result of adverse effects or lack of efficacy. A key reason for this high attrition rate is that we are only just beginning to understand the complexity of the response(s)…

Personalised medicine: are we ready for the revolution?

19 March 2008 | By

The impact of biomarker technology and biomarker strategies in pharmaceutical development is still in its infancy; but the impact is already proving significant. Biomarker strategy forms the basis for personalised medicine, the industry/regulatory focus centres on improving the success rate and reducing the high attrition rate often encountered in early…

High content screening as improved lead finding strategy

19 March 2008 | By

High content screening (HCS) is based on subcellular imaging using automated microscopy, in combination with automated image analysis. High content screening was first introduced over a decade ago as one of the promising new technologies, intended to address the bottleneck of secondary assays in the development of new drugs. Since…

Going paperless: is now the time?

19 March 2008 | By

Over the past 40 years, the development of increasingly powerful computers has played a major role in the advancement of laboratory experimentation. Initially, the high processing capabilities of computers were exploited to perform complex calculations at unprecedented speeds, often offline to a company’s main frame.

Thermal analysis and calorimetry: latest developments

19 March 2008 | By Danielle Giron, Chemical Research & Development, Novartis Pharma AG, Basel, Switzerland

Thermal analysis techniques cover all methods in which a physical property is monitored as a function of temperature or time, whilst the sample is being heated or cooled under controlled conditions. Calorimetric methods measure the energy involved in every process. The quicker new developments attain the market, such as the…

PAT: not a purpose in itself

19 March 2008 | By

The process analytical technology guidelines have been a hotly debated topic within the pharmaceutical industry ever since they were made public in 2004. This also holds true at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), Division of Janssen Pharmaceutical N.V. In recent years, the company has introduced PAT tools…

Genome-wide High Content Analysis of cellular pathways

23 January 2008 | By

Creating the molecular tools to combat human disease and infection remains the cornerstone activity of the pharmaceutical industry. The methodologies employed to discover new drugs has continually evolved as new biological techniques have emerged1; nevertheless the development of each novel compound is still only realised after many years of careful…

High throughput materials discovery “reducing product time to market”

23 January 2008 | By Dr. Neil Campbell, Senior Experimental Officer, Automation and Process Development Specialist, Centre for Materials Discovery, University of Liverpool

With ever mounting market pressure on industries, from increasing global competition, along with consumer desire for value for money and improved performance results there is a greater driving force to stay one step ahead by reducing product time to market. This enforced impetus has many companies having to continually improve…